Elinzanetant: First Approval.

Drugs · 2026 · PMC12799696 · PMID 41222830

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The LSM change with elinzanetant 120 mg versus placebo from baseline in VMS frequency indicated a significant decrease at week 4 (–3.93 VMS/day, p < 0.001) and week 12 (–2.95 VMS/day, p = 0.01); reductions in VMS severity followed a similar trend (–0.51 at week 4 and –0.56 at week 12), but did not reach statistical significance (coprimary endpoints).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.